Betalin Therapeutics

company

About

Betalin Therapeutics develops a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP).

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€500K
Industries
Biotechnology,Health Care,Wellness
Founded date
Jul 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells.

After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€500K
Betalin Therapeutics has raised a total of €500K in funding over 2 rounds. Their latest funding was raised on Jan 26, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 26, 2022 Series Unknown €500K 1 European Innovation Council Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Betalin Therapeutics is funded by 1 investors. European Innovation Council are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Yes Series Unknown